Annovis Bio, Inc. (ANVS)

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of...

Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.

Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any ad...

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's ...

Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.

WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.

EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.

Investor confusion surrounding Annovis's interim analysis of its Phase 3 Parkinson's (PD) study highlights the need, in my view, for improved PR processes at Annovis. The company will have ~9 months t...

Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Lead asset buntanetap represents a differentiated, potentially disease-modifying mechanism of action in neurodegenerative diseases. Interim Phase 3 Parkinson's data to be presented today (3/30/23) at ...